Published online before print March 27, 2008, doi: 10.1161/ATVBAHA.107.157115
© 2008 American Heart Association, Inc.
Cell Biology and Signaling |
Epoxycholesterol Impairs Cholesteryl Ester Hydrolysis in Macrophage Foam Cells, Resulting in Decreased Cholesterol Efflux
From the Lipoprotein and Atherosclerosis Research Group, University of Ottawa Heart Institute, and Departments of Biochemistry, Microbiology, and Immunology, and Pathology and Laboratory Medicine, University of Ottawa, Ontario, Canada.
Correspondence to Y.L. Marcel, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario, K1Y 4W7, Canada. E-mail ylmarcel{at}ottawaheart.ca
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Objective— Strategies to inhibit or reverse cholesterol accumulation in macrophages have been shown to be atheroprotective. Notably, the administration of LXR agonists upregulates key players in the reverse cholesterol transport pathway, including the ABCA1 and ABCG1 transporters. However, the effects of natural LXR activators, oxysterols, on lipid-laden macrophages remains elusive.
Methods and Results— We assessed the ability of 2 oxysterols, 22(R)-hydroxycholesterol (22-OH) and 24(S),25-epoxycholesterol (epoxycholesterol), to promote cholesterol efflux to apoA-I from LDL- and modified LDL-labeled and loaded macrophages and thus rescue the phenotype associated with the accumulation of cellular cholesterol in these cells. In macrophages labeled with LDL-derived cholesterol, epoxycholesterol treatment enhances ABCA1-mediated cholesterol efflux. In contrast, in AcLDL-loaded macrophages, epoxycholesterol treatment decreases cholesterol efflux to apoA-I, despite a dramatic increase in the expression of ABCA1 in response to epoxycholesterol treatment. We show that the decreased efflux is attributable to impaired cholesterol mobilization from lipid droplets, resulting from decreased cholesteryl ester hydrolase activity.
Conclusion— Epoxycholesterol impairs cholesteryl ester hydrolysis activity in macrophage foam cells, thus reducing the availability of cholesterol for efflux to cholesterol acceptors.
We report that in cholesterol-loaded macrophages, epoxycholesterol decreases ABCA1- and ABCG1-mediated cholesterol efflux, despite increasing the expression of both transporters. We show that epoxycholesterol impairs cholesteryl ester hydrolysis activity in macrophage foam cells, thus reducing the availability of cholesterol for efflux to apoA-I and HDL.
Key Words: macrophage • epoxycholesterol • cholesteryl ester hydrolysis • cholesterol • ABCA1
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Whereas low density lipoprotein (LDL) endocytosis is a regulated process, the uptake of modified LDL via macrophage scavenger receptors1 or via macropinocytosis2 lacks feedback inhibition by intracellular cholesterol accumulation. The internalization of modified LDL, such as oxidized LDL (OxLDL), acetylated LDL (AcLDL), or aggregated LDL (AgLDL), leads to the formation of foam cells,3,4 which are a major component of atherosclerotic lesions.
The liver X receptors (LXRs) 
and β, members of the nuclear receptor family of transcription factors, are key regulators of whole body lipid homeostasis. LXR-β is expressed ubiquitously whereas LXR- is predominantly expressed in tissues important in lipid metabolism including liver, adipose tissue, and macrophages.5,6 The naturally occurring oxysterols 22(R)-hydroxycholesterol (22-HC) and 24(S),25-epoxycholesterol (epoxycholesterol) are endogenous LXR ligands and have been shown to be potent physiological activators of both LXRs.7,8 LXRs function by forming an obligate heterodimer with the retinoid X receptor (RXR), and this complex drives LXR-dependent transactivation of multiple genes involved in cellular cholesterol homeostasis, including ABCA1, ABCG1, and apoE in the lipid efflux pathway, which normally prevent cholesterol accumulation as intracellular lipid droplets.9
Given that ABCA1-mediated cholesterol efflux to lipid-poor apolipoprotein A-I (apoA-I) is the preferred efflux pathway of the macrophage foam cell,10 we sought to promote this pathway in cholesterol-loaded cells using 22-HC and epoxycholesterol. Oxysterols have been shown to be beneficial for enhancing cholesterol efflux6,11–13 and preventing foam cell formation,14 but it is not established whether they are similarly effective when macrophages become cholesterol-loaded. Large quantities of excess lipoprotein-derived cholesterol are esterified by the ER-resident protein, acyl-coenzyme A (CoA):cholesterol acyl transferase (ACAT) and stored as cholesteryl esters (CE) in cytoplasmic lipid droplets.15 Unesterified cholesterol can be released from the lipid droplets via CE hydrolysis, and subsequently effluxed to a cholesterol acceptor or reesterified by ACAT.16
Unexpectedly, we found that whereas 22-HC enhanced cholesterol efflux from AcLDL-loaded macrophages, epoxycholesterol promoted cholesterol efflux only in unloaded or LDL-labeled macrophages. Despite inducing a dramatic increase in ABCA1 protein, epoxycholesterol impaired CE hydrolysis in lipid droplets of macrophage foam cells and reduced efflux to apoA-I, resulting in a net increase of CE and exacerbation of the foam cell phenotype.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Materials
Oxysterols: 22(R)-hydroxycholesterol, 22(S)-hydroxycholesterol, and 24(S),25-epoxycholesterol (Steraloids Inc). DMEM and RPMI 1640 medium (Invitrogen/Gibco), and Penicillin/Streptomycin (P/S) (Cambrex Bio Science). Fetal bovine serum (FBS), bovine serum albumin (BSA), and phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma. Radioactive compounds: [1,2-3H]-Cholesterol, [5-3H(N)]mevalono-lactone-Rs, [3H]-Oleate, and [3H]-Acetic acid (PerkinElmer Life Sciences). Human recombinant apoA-I was produced as previously described.17 The Sandoz 58 to 035 ACAT inhibitor was a kind gift from Novartis (Basel, Switzerland).
Cell Culture
Bone marrow–derived macrophages (BMDM): hematopoietic stem cells were flushed from the femurs of C57Bl6 mice (Jackson Laboratories) and differentiated into mature macrophages by incubation in DMEM media supplemented with 10% FBS, 1% P/S, and 15% L929-conditioned medium for 7 days. Monocyte-derived macrophages (MDM): mononuclear cells were isolated from the blood of normolipemic volunteers, and differentiated to macrophages, as previously described.18 THP-1 human monocytes (ATCC) were cultured in complete growth medium (RPMI 1640 supplemented with 10% FBS, 0.05 mmol/L 2-mercaptoethanol, and 1% P/S), and were differentiated by treatment with PMA (100 nmol/L) for 7 days.
Lipoprotein Preparation
Plasma was collected from normolipemic volunteers. LDL and HDL were isolated by sequential density ultracentrifugation, as previously described.19,20 Modification of LDL: LDL was acetylated by repetitive additions of acetic anhydride,21 aggregated by vortexing,22 or oxidized by incubation with 5 µmol/L CuSO4 at room temperature for 24 hours, adapted from Kunjathoor et al.23
Efflux of Exogenously Delivered Cholesterol
Differentiated macrophages were incubated for 24 hours in medium (1% FBS, 1% P/S DMEM) containing LDL or AcLDL (50 µg/mL) that were preincubated with 3H-cholesterol (5µCi/mL). Cells were washed and incubated in equilibration media (2 mg/mL BSA, 1% P/S DMEM) containing oxysterols (10 µmol/L, unless otherwise specified). Cells were washed, and cholesterol efflux was determined in the presence or absence of human apoA-I (50 µg/mL) in serum-free medium (2 mg/mL BSA, 1% P/S DMEM). After 5 hours, the supernatant was removed and briefly centrifuged to remove nonadherent cells. Macrophages were dissolved in 0.5N NaOH. Radioactivity of aliquots of both supernatants, and dissolved cells was measured by scintillation counting. Cholesterol efflux is expressed as a percentage of 3H-cholesterol in medium/(3H-cholesterol in medium+3H-cholesterol in cells)x100%. The radioactivity of apoA-I–free media was subtracted from that of the apoA-I–containing media.
Efflux of Newly Synthesized Cholesterol
Macrophages were incubated in medium (1% FBS, 1% P/S DMEM) containing 3H-mevalonate (20µCi/mL) and oxysterols (10 µmol/L) for 48 hours. Cells were washed, and cholesterol efflux was measured over 24 hours, in the presence or absence of human apoA-I in serum-free medium (2 mg/mL BSA, 1% P/S DMEM). ApoA-I in media aliquots was immunoprecipitated under native conditions with a polyclonal antihuman apoA-1 rabbit antiserum (Calbiochem) and Protein G Sepharose (Amersham Biosciences). The immunoprecipitates were collected after centrifugation and washed 4 times with phosphate-buffered saline and resuspended in a final volume of 0.5 mL for scintillation counting. The radioactivity of the apoA-I–free media was subtracted from that of the apoA-I–containing media. Total cellular protein levels were determined the Markwell Lowry assay.24
Intracellular Cholesterol Distribution
Lipids were extracted from the cell lysates25 and separated by thin layer chromatography on silica gel plates using a nonpolar solvent system (hexane/diethyl ether/acetic acid, 70:30:1) for separation of cholesterol and CE. The bands corresponding to cholesterol and CE were excised and counted for radioactivity. Alternatively, cellular cholesterol and CE were extracted and measured using a fluorometric assay (Cholesterol/Cholesteryl Ester Quantitation Kit, BioVision), according to the manufacturer’s instructions.
Western Blot Analysis
Cells were incubated with or without LDL or AcLDL (50 µg/mL) for 24 hours, then treated with oxysterols overnight. Cells were washed with PBS, scrapped with lysis buffer (Tris-EDTA-EGTA+Complete protease inhibitor; Roche) and mechanically homogenized. Total protein samples (25 µg per well) were electrophoresed on a precast 8% SDS-polyacrylamide gel (Invitrogen) and transferred to nitrocellulose membranes at 125V for 4 hours. Membranes were incubated overnight with anti-ABCA1 (1:500, Novus Biologicals), anti-ABCG1 (1:2500, Novus Biologicals), anti–β-Actin (1:500, BioLegend), or anti–Heat Shock Protein 60 (HSP60) (1:500, Sigma). An anti-rabbit secondary antibody conjugated with horseradish peroxidase (Amersham Biosciences) and SuperSignal West Pico Chemiluminescent Substrate (Pierce) were used for detection.
Statistical Analysis
Results are shown as mean±SEM, and all experiments were run in triplicates. The statistical significance of the differences between groups was determined using Student t test with or without Welsh correction or 1-way ANOVA with Tukey post test using GraphPad InStat v.3.06 statistical analysis software (GraphPad Software Inc).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Epoxycholesterol Promotes Cholesterol Efflux to Lipid-Poor ApoA-I in LDL-Treated But Not in AcLDL-Loaded Macrophages
Bone marrow–derived macrophages (BMDM) were labeled with 3H-mevalonate in the presence of oxysterols for 48 hours, after which efflux of de novo synthesized cholesterol to apoA-I was measured. In unloaded macrophages (not preincubated with lipoproteins), both 22-HC and epoxycholesterol increased efflux of newly synthesized cholesterol (Figure 1A). Epoxycholesterol, which has a higher affinity for LXR than 22-HC,26 was a stronger inducer of efflux of newly synthesized cholesterol to apoA-I. The observed increase in cholesterol efflux was not attributable to an increase of cholesterol synthesis in response to treatment with oxysterols, because total cholesterol synthesis was decreased in cells treated with oxysterols (data not shown). This is in agreement with the well-documented downregulation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase by oxysterols.27–29
|
The effect of oxysterols on cholesterol efflux in macrophage foam cells has not been well characterized. Here in BMDM foam cells generated by incubating with AcLDL, the net cellular cholesterol level (µg/mg cell protein) was 8.7-fold higher compared to unloaded macrophages (488±18 versus 56±5). As expected, because of the feedback inhibition of the LDL receptor, the cholesterol content of LDL-labeled macrophages was similar to that of unloaded macrophages (63±9 compared to 56±3). Surprisingly, epoxycholesterol decreased cholesterol efflux to apoA-I in AcLDL-loaded foam cells, whereas 22-HC had a stimulatory effect (Figure 1B). This efflux reduction was also observed in macrophages treated with oxLDL and agLDL, 2 other well-known foam cell inducers, but not in LDL-treated macrophages. Epoxycholesterol not only decreased cholesterol efflux in murine macrophage foam cells, but also in human THP-1 macrophages (Figure 1C) and in primary human monocyte-derived macrophages (MDM; Figure 1D) loaded with AcLDL-derived cholesterol.
In unloaded or LDL-treated macrophages, epoxycholesterol stimulated cholesterol efflux, suggesting that the reduction of efflux in response to epoxycholesterol is specific to the macrophage foam cell (Figure 1B). Indeed, when macrophages were loaded with increasing amounts of AcLDL-derived cholesterol (Figure 2A), epoxycholesterol concomitantly reduced cholesterol efflux to apoA-I proportionally to the amount of AcLDL internalized into the cell (Figure 2B).
|
Induction of ABCA1 and ABCG1 Expression by Epoxycholesterol Treatment in AcLDL-Loaded Macrophages Is Not Associated With Enhanced ABCA1- and ABCG1-Mediated Cholesterol Efflux
In AcLDL-loaded BMDM, we observed a dose-dependent decrease of cholesterol efflux to lipid-poor apoA-I in response to epoxycholesterol treatment (Figure 3A). Another member of the ATP-binding cassette (ABC) family, ABCG1, has previously been described as a LXR-responsive gene13,30 and has an established role in the efflux of cholesterol to high density lipoprotein (HDL) acceptors.31,32 Interestingly, increasing doses of epoxycholesterol also correlated with a decrease in cholesterol efflux to HDL in AcLDL-loaded BMDM (Figure 3B), indicating that epoxycholesterol does not uniquely affect the ABCA1-mediated pathway. Rather, epoxycholesterol seems to impair cholesterol efflux regardless of the cholesterol acceptor.
|
The decline of cholesterol efflux occurred in spite of the upregulation of the transporters implicated in these processes. Expression of both ABCA1 (Figure 3C) and ABCG1 (Figure 3D) was induced by epoxycholesterol, in a dose-dependent fashion, and translocation of the transporters to the plasma membrane was not hindered (data not shown).
Epoxycholesterol Impairs the Mobilization of Cholesterol
Excess cellular cholesterol is stored as CE, which can be mobilized for efflux by CE hydrolase activity. We therefore evaluated the effects of 22-HC and epoxycholesterol on CE stores. In unloaded BMDM, epoxycholesterol dramatically increased the proportion of newly synthesized cholesterol in CE pools (Figure 4A). Epoxycholesterol also promoted the accumulation of CE in BMDM incubated with LDL, AcLDL, OxLDL, and AgLDL (Figure 4B). In contrast, treatment with 22-HC did not induce a comparable rise in cellular CE. The relative changes in CE levels shown in Figure 4A and 4B were indeed representative of net CE accumulation, as confirmed by direct measurement of esterified cholesterol cellular content (Figure 4C and 4D). Additionally, epoxycholesterol enhanced cellular CE mass in THP-1 macrophages in both unloaded and AcLDL-loaded cells (Table).
|
|
Because the accumulation of CE was specifically attributable to epoxycholesterol treatment, we speculated that this might be implicated in the impairment of cholesterol efflux from epoxycholesterol-treated macrophage foam cells. One of two scenarios (or perhaps a combination of both) could be proposed: Epoxycholesterol promotes the esterification of cholesterol via stimulation of ACAT, or epoxycholesterol decreases CE hydrolysis. In both, availability of free cholesterol for efflux to apoA-I would be decreased. To distinguish between the two, we performed a series of experiments in the presence of an ACAT inhibitor, which was added at key times during the experiments.
First, the ACAT inhibitor was added during treatment with epoxycholesterol, after the cells had been incubated with 3H-cholesterol-AcLDL for 24 hours. Subsequently, efflux to apoA-I was measured for 5 hours. Whereas the ACAT inhibitor-treated cells displayed increased cholesterol efflux, the addition of epoxycholesterol increased but failed to restore efflux to apoA-I (Figure 5A), indicating that the ability of epoxycholesterol to reduce cholesterol efflux in macrophage foam cells is largely independent of cholesterol esterification.
|
Next, the ACAT inhibitor was administered during labeling of BMDM with LDL- or AcLDL-derived 3H-cholesterol for 6 hours, as well as during treatment with epoxycholesterol (12 hours) and efflux to apoA-I (5 hours). Under these conditions, cholesterol esterification in the ER for storage in the lipid droplet was inhibited, and essentially all of the lipoprotein-derived 3H-cholesterol remained unesterified (Figure 5B). We observed an increase in both LDL- and AcLDL-derived cholesterol efflux in response to epoxycholesterol treatment (Figure 5C), demonstrating that epoxycholesterol does not hinder efflux of unesterified cholesterol, and mediates its effect downstream of cholesterol esterification in the ER.
Finally, to directly assess the degree of CE hydrolysis in response to epoxycholesterol treatment, BMDM were incubated with unlabeled AcLDL in the presence of 3H-oleate for 24 hours, such that AcLDL-derived cholesterol could be esterified to the radio-labeled oleate. Subsequent treatment with epoxycholesterol in the presence of an ACAT inhibitor and apoA-I resulted in equivalent CE cellular content as epoxycholesterol treatment alone (Figure 5D), therefore allowing us to conclude that epoxycholesterol treatment impairs mobilization of cholesterol from the CE pools. Specifically, epoxycholesterol decreases CE hydrolysis from the lipid droplet, and reduces the availability of free cholesterol for efflux to lipid-poor apoA-I or HDL.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Because activated LXRs induce the expression of numerous genes involved in the reverse cholesterol transport pathway, notably ABCA1 and ABCG1, they have become attractive targets for pharmacological treatment of atherosclerosis.33 Whereas the therapeutic potential of LXR activation has been demonstrated by the targeted disruption of LXR in macrophages in athero-susceptible mice,34 systemic LXR activation is less favorable because of an associated rise in plasma triglycerides attributed to LXR activation of sterol regulatory element binding protein 1c (SREBP-1c), which induces genes involved in fatty acid and triglyceride synthesis.35–38
The naturally occurring oxysterols, 22-HC and epoxycholesterol, are potent LXR ligands.8 Interestingly, increased epoxycholesterol production in macrophages was recently reported to selectively upregulate cholesterol efflux genes without a simultaneous increase in genes that promote triglyceride synthesis, in contrast to a nonsteroidal synthetic LXR agonist.14,39 Given that epoxycholesterol has a higher affinity for LXR than 22-HC26 and does not promote triglyceride synthesis,39 we hypothesized that epoxycholesterol should be the most effective oxysterol to induce cholesterol efflux in lipid-loaded macrophages and decrease the foam cell phenotype.
Whereas epoxycholesterol enhanced cholesterol efflux in unloaded or LDL-treated and labeled macrophages in keeping with earlier reports of the effects of oxysterols,6,11–13 it unexpectedly decreased cholesterol efflux in lipid-laden primary murine macrophages generated by incubation with AcLDL, OxLDL, or AgLDL (Figure 1A and 1B). Moreover, epoxycholesterol also decreased cholesterol efflux in human THP-1 and monocyte-derived macrophages loaded with AcLDL-derived cholesterol (Figure 1C and 1D). In lipid-loaded macrophages, epoxycholesterol impaired both ABCA1-mediated cholesterol efflux to lipid-poor apoA-I and ABCG1-mediated cholesterol efflux to HDL (Figure 3A and 3B). The decrease in cholesterol efflux on epoxycholesterol treatment in macrophage foam cells occurred despite the significant upregulation of the ABCA1 and ABCG1 transporters (Figure 3C and 3D), in agreement with earlier reports of oxysterol stimulation of ABCA111,13 and ABCG132,40 expression. Interestingly, it has previously been shown that in macrophage foam cells 7-ketocholesterol impairs cholesterol efflux to apoA-I, compared with macrophages loaded with AcLDL alone, thus indicating that this oxysterol also inhibits reverse cholesterol transport in AcLDL-loaded macrophages.41
CE stored in cytoplasmic lipid droplets must be mobilized by enzymes with CE hydrolase activities before export of cholesterol from the cell via ABCA1- and ABCG1-mediated efflux. We have found that epoxycholesterol reduces cholesterol efflux downstream of the ER-resident enzyme responsible for the esterification of cholesterol (Figure 5A through 5C). When esterification of cholesterol for storage in the lipid droplets was inhibited via the administration of an ACAT inhibitor, epoxycholesterol enhanced efflux of both LDL- and AcLDL-derived cholesterol. In contrast, epoxycholesterol treatment in the presence of the ACAT inhibitor, after macrophage lipid-loading, leads to a reduction of cholesterol efflux and accumulation of CE in lipid droplets. We thus conclude that epoxycholesterol reduces cholesterol availability for efflux via downregulation of CE hydrolysis.
The exact identity of the enzymes that catalyze CE lipolysis in macrophages remains ambiguous. Whereas the presence of the hormone-sensitive lipase (HSL) in human macrophages is controversial,42 a neutral CEH gene was cloned from THP-1 and PBMC libraries,43 the overexpression of which enhanced both ABCA1- and ABCG1-mediated efflux in THP-1 cells.44 We have investigated whether epoxycholesterol regulates the expression of this human CEH in THP-1 macrophages. Our results indicate that epoxycholesterol does not decrease cholesterol efflux via transcriptional regulation of CEH expression in human macrophages (supplemental Figure IA, available online at http://atvb.ahajournals.org).
Interestingly, we were able to detect HSL mRNA in THP-1 macrophages using the primers designed by Reue et al.45 However, we did not observe any significant change in HSL mRNA in our treated versus untreated cells (supplemental Figure IB). Hence, changes in HSL expression at the transcriptional level cannot explain the decrease in CE hydrolysis measured in epoxycholesterol-treated cells. It is, however, unlikely that HSL plays a major role in the CE hydrolysis in these THP-1 macrophages given that its mRNA levels were strikingly lower, by as much as 20 000-fold, compared to CEH mRNA. Conversely, as one early study has shown, for certain hydrolases there is little correlation between mRNA levels and lipolytic activity.46
It remains to be determined how epoxycholesterol decreases CE hydrolysis in lipid-loaded macrophages. We do know that this occurs independently of LXR activation, because the simultaneous treatment of lipid-loaded THP-1 cells with epoxycholesterol and an LXR antagonist does not increase cholesterol efflux, and the addition of an LXR synthetic agonist in conjunction with epoxycholesterol fails to rescue the efflux defect (supplemental Figure II). Although epoxycholesterol does not reduce CE lipolysis in lipid-loaded macrophages via transcriptional downregulation of CEH or HSL, the possibility of altered posttranslational regulation of these enzymes remains to be investigated, as well as the contribution of other candidate enzymes for CE hydrolysis in these macrophages. It is worth to note that other lipid droplet associated proteins, such as perilipin and adipocyte differentiation-related protein (ADRP), were reported to influence lipid hydrolysis by regulating the accessibility of the hydrolytic enzymes to lipids within the droplet core. The examination of the effects of epoxycholesterol on these proteins is underway.
Potential LXR agonists for therapeutic intervention in atherosclerosis need to be selected with extreme caution. As shown here, an increase in the expression of ABCA1 and ABCG1 transporters does not necessarily translate into enhancement of cholesterol efflux from the macrophage. We have observed that once the macrophage becomes cholesterol-loaded, its response to oxysterols differs than that observed in unloaded and LDL-loaded macrophages. Our results indicate that 22-HC is better capable of promoting cholesterol efflux in lipid-laden macrophages, whereas epoxycholesterol appears to impair this process. In conclusion, epoxycholesterol elicits cholesterol efflux from noncholesterol loaded cells but aggravates the phenotype of the macrophage foam cell. Hence, epoxycholesterol may have quite different effects on the prophylaxis versus regression of atherosclerosis.
|
Acknowledgments |
|---|
We thank Vivian Franklin for expert technical support and Drs R. McPherson and R. Milne for critical reading of this manuscript.
Sources of Funding
This work was supported by grants from Canadian Institutes of Health Research and the Heart and Stroke Foundation of Ontario to Y.L.M. M.O. was the recipient of a Heart and Stroke Foundation of Ontario Master’s Studentship Award.
Disclosures
None.
|
Footnotes |
|---|
Original received October 1, 2007; final version accepted March 17, 2008.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Greaves DR, Gordon S. Thematic review series: the immune system and atherogenesis. Recent insights into the biology of macrophage scavenger receptors. J Lipid Res. 2005; 46: 11–20.
2. Jones NL, Allen NS, Willingham MC, Lewis JC. Modified LDLs induce and bind to membrane ruffles on macrophages. Anat Rec. 1999; 255: 44–56.[CrossRef][Medline] [Order article via Infotrieve]
3. Hoff HF, Zyromski N, Armstrong D, O’Neil J. Aggregation as well as chemical modification of LDL during oxidation is responsible for poor processing in macrophages. J Lipid Res. 1993; 34: 1919–1929.[Abstract]
4. Shashkin P, Dragulev B, Ley K. Macrophage differentiation to foam cells. Curr Pharm Des. 2005; 11: 3061–3072.[CrossRef][Medline] [Order article via Infotrieve]
5. Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med. 2006; 57: 313–329.[CrossRef][Medline] [Order article via Infotrieve]
6. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000; 16: 459–481.[CrossRef][Medline] [Order article via Infotrieve]
7. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996; 383: 728–731.[CrossRef][Medline] [Order article via Infotrieve]
8. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA, Willson TM. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem. 1997; 272: 3137–3140.
9. Ory DS. Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home? Circ Res. 2004; 95: 660–670.
10. Wang MD, Kiss RS, Franklin V, McBride HM, Whitman SC, Marcel YL. Different cellular traffic of LDL-cholesterol and acetylated LDL-cholesterol leads to distinct reverse cholesterol transport pathways. J Lipid Res. 2007; 48: 633–645.
11. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000; 275: 28240–28245.
12. Schwartz K, Lawn RM, Wade DP. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun. 2000; 274: 794–802.[CrossRef][Medline] [Order article via Infotrieve]
13. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A. 2000; 97: 12097–12102.
14. Rowe AH, Argmann CA, Edwards JY, Sawyez CG, Morand OH, Hegele RA, Huff MW. Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation. Circ Res. 2003; 93: 717–725.
15. Simons K, Ikonen E. How cells handle cholesterol. Science. 2000; 290: 1721–1726.
16. van Reyk DM, Jessup W. The macrophage in atherosclerosis: modulation of cell function by sterols. J Leukoc Biol. 1999; 66: 557–561.[Abstract]
17. Bergeron J, Frank PG, Emmanuel F, Latta M, Zhao Y, Sparks DL, Rassart E, Denefle P, Marcel YL. Characterization of human apolipoprotein A-I expressed in Escherichia coli. Biochim Biophys Acta. 1997; 1344: 139–152.[Medline] [Order article via Infotrieve]
18. Kiss RS, Kavaslar N, Okuhira K, Freeman MW, Walter S, Milne RW, McPherson R, Marcel YL. Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. Arterioscler Thromb Vasc Biol. 2007; 27: 1139–1145.
19. Harder CJ, Vassiliou G, McBride HM, McPherson R. Hepatic SR-BI-mediated cholesteryl ester selective uptake occurs with unaltered efficiency in the absence of cellular energy. J Lipid Res. 2006; 47: 492–503.
20. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955; 34: 1345–1353.[Medline] [Order article via Infotrieve]
21. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979; 76: 333–337.
22. Otero-Vinas M, Llorente-Cortes V, Pena E, Padro T, Badimon L. Aggregated low density lipoproteins decrease metalloproteinase-9 expression and activity in human coronary smooth muscle cells. Atherosclerosis. 2007; 194: 326–333.[CrossRef][Medline] [Order article via Infotrieve]
23. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002; 277: 49982–49988.
24. Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978; 87: 206–210.[CrossRef][Medline] [Order article via Infotrieve]
25. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37: 911–917.[Medline] [Order article via Infotrieve]
26. Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, Corey EJ, Mangelsdorf DJ. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci U S A. 1999; 96: 266–271.
27. Bjorkhem I. Do oxysterols control cholesterol homeostasis? J Clin Invest. 2002; 110: 725–730.[CrossRef][Medline] [Order article via Infotrieve]
28. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA. 1999; 96: 11041–11048.
29. Weber LW, Boll M, Stampfl A. Maintaining cholesterol homeostasis: sterol regulatory element-binding proteins. World J Gastroenterol. 2004; 10: 3081–3087.[Medline] [Order article via Infotrieve]
30. Venkateswaran A, Repa JJ, Lobaccaro JM, Bronson A, Mangelsdorf DJ, Edwards PA. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem. 2000; 275: 14700–14707.
31. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005; 1: 121–131.[CrossRef][Medline] [Order article via Infotrieve]
32. Nakamura K, Kennedy MA, Baldan A, Bojanic DD, Lyons K, Edwards PA. Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein. J Biol Chem. 2004; 279: 45980–45989.
33. Joseph SB, Tontonoz P. LXRs: new therapeutic targets in atherosclerosis? Curr Opin Pharmacol. 2003; 3: 192–197.[CrossRef][Medline] [Order article via Infotrieve]
34. Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, Daige CL, Thomas D, Heyman RA, Mangelsdorf DJ, Wang X, Lusis AJ, Tontonoz P, Schulman IG. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci U S A. 2002; 99: 11896–11901.
35. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, Collins JL, Osborne TF, Tontonoz P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem. 2002; 277: 11019–11025.
36. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000; 14: 2819–2830.
37. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 2000; 14: 2831–2838.
38. Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Kimura S, Ishibashi S, Yamada N. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol. 2001; 21: 2991–3000.
39. Beyea MM, Heslop CL, Sawyez CG, Edwards JY, Markle JG, Hegele RA, Huff MW. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. J Biol Chem. 2007; 282: 5207–5216.
40. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA. 2004; 101: 9774–9779.
41. Gelissen IC, Brown AJ, Mander EL, Kritharides L, Dean RT, Jessup W. Sterol efflux is impaired from macrophage foam cells selectively enriched with 7-ketocholesterol. J Biol Chem. 1996; 271: 17852–17860.
42. Yeaman SJ. Hormone-sensitive lipase–new roles for an old enzyme. Biochem J. 2004; 379: 11–22.[CrossRef][Medline] [Order article via Infotrieve]
43. Ghosh S. Cholesteryl ester hydrolase in human monocyte/macrophage: cloning, sequencing, and expression of full-length cDNA. Physiol Genomics. 2000; 2: 1–8.
44. Zhao B, Song J, St Clair RW, Ghosh S. Stable overexpression of human macrophage cholesteryl ester hydrolase results in enhanced free cholesterol efflux from human THP1 macrophages. Am J Physiol Cell Physiol. 2007; 292: C405–C412.
45. Reue K, Cohen RD, Schotz MC. Evidence for hormone-sensitive lipase mRNA expression in human monocyte/macrophages. Arterioscler Thromb Vasc Biol. 1997; 17: 3428–3432.
46. Zolfaghari R, Harrison EH, Han JH, Rutter WJ, Fisher EA. Tissue and species differences in bile salt-dependent neutral cholesteryl ester hydrolase activity and gene expression. Arterioscler Thromb. 1992; 12: 295–301.
This article has been cited by other articles:
 |
|
 |
|
  G. L. Weibel, M. R. Joshi, E. T. Alexander, P. Zhu, I. A. Blair, and G. H. Rothblat Overexpression of Human 15(S)-Lipoxygenase-1 in RAW Macrophages Leads to Increased Cholesterol Mobilization and Reverse Cholesterol Transport Arterioscler. Thromb. Vasc. Biol., June 1, 2009; 29(6): 837 - 842. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||